OncoMatch/Clinical Trials/NCT05851378
Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma
Is NCT05851378 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG) for adult gliomas, mixed.
Treatment: Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG) — This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in participants with isocitrate dehydrogenase (IDH) mutant glioma.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: IDH1 mutation
Required: IDH2 mutation
Lab requirements
Kidney function
creatinine < 1.5 mg/dL within 60 days prior to the HP 13C Imaging scan
Cardiac function
No NYHA Grade II or greater congestive heart failure; no history of myocardial infarction or unstable angina within 12 months prior to study enrollment
adequate renal function (creatinine < 1.5 mg/dL)...must not have NYHA Grade II or greater congestive heart failure...must not have history of myocardial infarction or unstable angina within 12 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify